Full Title: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Status: Active, Recruiting

Age Range: 2-25 years

Locations: University College London Hospital, Christie Hospital, Royal Manchester Children's Hospital, Birmingham Children's Hospital, Royal Hospital for Children, Alder Hey Children's Hospital, Royal Victoria Infirmary

Registry Number: NCT04154189

This trial aims to assess the effectiveness and safety of Lenvatanib in combination with Ifosfamide and Etoposide compared to Ifosfamide and Etoposide alone, in children, adolescents and young adults with osteosarcoma that has not responded to treatment or has come back after treatment.

The trial is randomised, meaning patients will be randomly assigned to a treatment arm by a computer. This is done so that neither the patient nor their doctor will be able to influence which treatment arm the patient is given and means that the results of the trial are not biased in any way.

If you would like any more information on clinical trials in general, please contact us at The Bone Cancer Research Trust. For more information on this trial and to understand if you are eligible, please talk to your clinical team

Donate now (This link opens in a new window) More about Osteosarcoma